We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Metabolic Biomarker Panel Shows Promise for Diagnosis of Dementia

By LabMedica International staff writers
Posted on 22 Sep 2021
Print article
A heat-map, where red shows high levels of a compound, and blue shows low levels of a compounds, reveals the link between certain metabolites and dementia. Compounds in sub-group A were typically higher in dementia patients and lower in healthy elderly people. Compounds in sub-group B-E showed the opposite effect (Photo courtesy of Okinawa Institute of Science and Technology)
A heat-map, where red shows high levels of a compound, and blue shows low levels of a compounds, reveals the link between certain metabolites and dementia. Compounds in sub-group A were typically higher in dementia patients and lower in healthy elderly people. Compounds in sub-group B-E showed the opposite effect (Photo courtesy of Okinawa Institute of Science and Technology)
A biomarker panel based on five groups of metabolites was shown to be potentially useful for diagnosis and therapy of various forms of dementia, such as Alzheimer’s disease.

Dementia, which is caused by factors that damage neurons, is characterized by a slowly progressing, chronic, and usually irreversible decline in cognitive function. The exact cause of neuron damage, and methods for its detection and treatment have remained elusive.

To rectify this situation, investigators at the Okinawa Institute of Science and Technology (Japan) employed nontargeted liquid chromatography–mass spectroscopy (LC-MS) to quantify small molecular markers in whole blood samples taken from of dementia patients. For this study, the investigators exhaustively analyzed blood samples collected from eight patients with dementia, from eight healthy elderly individuals, and from eight healthy young individuals. Overall, the investigators measured the levels of 124 different metabolites for each patient.

Analysis of the results revealed that 33 metabolites, classified into five groups (A to E), differed significantly in dementia patients, compared with healthy elderly subjects. Seven Group A metabolites present in plasma, including quinolinic acid, kynurenine, and indoxyl-sulfate, increased. The investigators suggested that these compounds may act as neurotoxins, damaging the central nervous system.

The remaining 26 compounds (in groups B to E) decreased in dementia patients, possibly causing a loss of support or protection of the brain in dementia. These compounds were thought to protect the nervous system against oxidative stress, maintain energy reserves, supply nutrients and act as neuroprotective factors.

“Identification of these compounds means that we are one step closer to being able to molecularly diagnose dementia,” said senior author Dr. Mitsuhiro Yanagida, head of the G0 Cell Unit at the Okinawa Institute of Science and Technology. “It is still too early to say, but it could suggest a possible mechanistic cause of dementia as these compounds may lead to impairment of the brain. In the future, we hope to start some intervention studies, either by supplementing dementia patients with metabolic compounds in sub-groups B-E, or by inhibiting the neurotoxins from sub-group A, to see if that can slow, prevent, or even reverse symptoms of dementia.”

The dementia study was published in the September 14, 2021, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America.

Related Links:

Okinawa Institute of Science and Technology

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.